Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access
Alyaa Al-Mughairy, Pediatric Hematology Oncology Senior Consultant at Ministry of Health Oman,and National Oncology Centre at Royal Hospital, shared Michael Makris‘s post on LinkedIn, adding:
”While standard maintenance doses for Emicizumab in hemophilia A target high plasma concentrations, real-world clinical experience in low economic countries, including our own suggests a low-dose regimens can still effectively maintain a 0.0 Annual bleeding rate for spontaneous bleeds.
This suggests that for many, we may be dosing beyond what is strictly necessary for clinical efficacy based in the standard approved doses.
It’s time to re-consider low doses regimen, ensuring sustainable access driven model of care to all patients without compromising patient safety or posing burden on the healthcare system.”
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Author: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation